Uses
FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.
Source: US FDA prescribing information
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Degarelix is a prescription medicine indicated for treatment of patients with advanced prostate cancer. It is available as kits. MedsAcross supplies Degarelix for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- ATC classification
- L02BX02 Degarelix · Hormonal cancer treatments, subgroup L02B, subgroup L02BX
- US FDA first approval
- 24 December 2008
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Dosage forms
- Kit
- Identifiers
- UNII SX0XJI3A11RxCUI 475230CAS 214766-78-6DrugBank DB06699Q1182795
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Degarelix is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.
Source: US FDA prescribing information
Dosing overview
FIRMAGON is for subcutaneous use only Starting Dosage: 240 mg given as two injections of 120 mg each. Maintenance Dosage: 80 mg administered as a single injection every 28 days
Source: US FDA prescribing information
Contraindications
FIRMAGON is contraindicated in patients with history of severe hypersensitivity to degarelix or to any of the product components. Patients with history of severe hypersensitivity reactions to degarelix or to any of the product components
Source: US FDA prescribing information
Warnings and precautions
Hypersensitivity: Anaphylaxis, urticaria and angioedema have been reported. Discontinue FIRMAGON if a severe hypersensitivity reaction occurs and manage as clinically indicated. QT Interval Prolongation: Androgen deprivation therapy treatment with FIRMAGON may prolong the QT interval. Embryo-Fetal Toxicity: FIRMAGON can cause fetal harm.
Source: US FDA prescribing information
Side effects
Most common adverse reactions (≥10%) are injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT)
Source: US FDA prescribing information
Interactions
No drug-drug interaction studies were conducted. Degarelix is not a substrate for the human CYP450 system. Degarelix is not an inducer or inhibitor of the CYP450 system in vitro. Therefore, clinically significant CYP450 pharmacokinetic drug-drug interactions are unlikely.
Source: US FDA prescribing information
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Degarelix, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Firmagon kit | Ferring Pharmaceuticals | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Degarelix available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Degarelix and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Degarelix have?
The catalogue lists 1 brand names for Degarelix, including Firmagon.
Is Degarelix approved by the US FDA?
Yes. The US FDA first approved Degarelix on 24 December 2008, according to Drugs@FDA.
Is Degarelix authorised in the European Union?
Yes. Degarelix has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Degarelix need cold chain shipping?
No listed presentation of Degarelix is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Degarelix in?
Degarelix is classified under ATC code L02BX02 (Degarelix).
References
- FIRMAGON prescribing information (Ferring Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 30 January 2024
- Firmagon: European public assessment report (EPAR). European Medicines Agency. Retrieved 20 October 2026
- Degarelix Accord: European public assessment report (EPAR). European Medicines Agency. Retrieved 20 October 2026
Request Degarelix for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.